In vitro metabolism of cyclosporine A by human kidney CYP3A5

Biochemical Pharmacology

Volumn 68, Issue 9, 2004, Pages 1889-1902

  Dai, Yang ^a   Iwanaga, Kazunori ^a,b   Lin, Yvonne S ^a,c   Hebert, Mary F ^a   Davis, Connie L ^a   Huang, Weili ^a   Kharasch, Evan D ^a   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cyclosporine A; CYP3A5; Drug metabolism; Genetic polymorphism; Nephrotoxicity

Indexed keywords

CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; KETOCONAZOLE;

ALLELE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; KIDNEY; KIDNEY MICROSOME; LIVER MICROSOME; MICHAELIS CONSTANT; PRIORITY JOURNAL; PROTEIN ANALYSIS;

BIOTRANSFORMATION; BLOTTING, WESTERN; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; KIDNEY; KINETICS; MICROSOMES; TESTOSTERONE;

EID: 4644280019     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.07.012     Document Type: Article

References (56)

1. A.O. Ojo, P.J. Held, F.K. Port, R.A. Wolfe, A.B. Leichtman, and E.W. Young Chronic renal failure after transplantation of a nonrenal organ N. Engl. J. Med. 349 10 2003 931 940
2. M.F. Hebert, A.L. Dowling, C. Gierwatowski, Y.S. Lin, K.L. Edwards, and C.L. Davis Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors Pharmacogenetics 13 11 2003 661 674
3. N.C. Fisher, P.G. Nightingale, B.K. Gunson, G.W. Lipkin, and J.M. Neuberger Chronic renal failure following liver transplantation: a retrospective analysis Transplantation 66 1 1998 59 66
4. M. Lynn, K. Abreo, G. Zibari, and J. McDonald End-stage renal disease in liver transplants Clin. Transplant 15 Suppl. 6 2001 66 69
5. T.A. Gonwa, M.L. Mai, L.B. Melton, S.R. Hays, R.M. Goldstein, and M.F. Levy End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment Transplantation 72 12 2002 1934 1939
6. A.J. Cohen, M.D. Stegall, C.B. Rosen, R.H. Wiesner, N. Leung, and W.K. Kremers Chronic renal dysfunction late after liver transplantation Liver Transplant. 8 10 2002 916 921
7. K.R. Copeland, and R.W. Yatscoff Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells Transplantation 53 3 1992 640 645
8. E. Healy, M. Dempsey, C. Lally, and M.P. Ryan Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line Kidney Int. 54 6 1998 1955 1966
9. S. Hortelano, M. Castilla, A.M. Torres, A. Tejedor, and L. Bosca Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells J. Am. Soc. Nephrol. 11 12 2000 2315 2323
10. M.J. Mihatsch, G. Thiel, and B. Ryffel Cyclosporine nephrotoxicity Adv. Nephrol. Necker. Hosp. 17 1988 303 320
11. C.K. Abrass, A.K. Berfield, C. Stehman-Breen, C.E. Alpers, and C.L. Davis Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies Am. J. Kidney Dis. 33 1 1999 11 20
12. G. Feutren, and C. Miller Low predictive value of cyclosporine level for efficacy or renal dysfunction in psoriasis and idiopathic nephrotic syndrome Transplant Proc. 22 3 1990 1299 1302
13. J.F. Bach, G. Feutren, L.H. Noel, T. Hannedouche, P. Landais, and J. Timsit Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels Transplant Proc. 22 3 1990 1296 1298
14. U. Christians, and K.F. Sewing Alternative cyclosporine metabolic pathways and toxicity Clin. Biochem. 28 6 1995 547 559
15. U. Christians, and K.F. Sewing Cyclosporin metabolism in transplant patients Pharmacol. Ther. 57 2/3 1993 291 345
16. G.L. Lensmeyer, D.A. Wiebe, and I.H. Carlson Deposition of nine metabolites of cyclosporine in human tissues, bile, urine, and whole blood Transplant Proc. 20 2 Suppl. 2 1988 614 622
17. U. Christians, S. Strohmeyer, R. Kownatzki, H.M. Schiebel, J. Bleck, and J. Greipel Investigations on the metabolic pathways of cyclosporine. I. Excretion of cyclosporine and its metabolites in human bile - isolation of 12 new cyclosporine metabolites Xenobiotica 21 9 1991 1185 1198
18. U. Christians, S. Strohmeyer, R. Kownatzki, H.M. Schiebel, J. Bleck, and K. Kohlhaw Investigations on the metabolic pathways of cyclosporine. II. Elucidation of the metabolic pathways in vitro by human liver microsomes Xenobiotica 21 9 1991 1199 1210
19. T. Kronbach, V. Fischer, and U.A. Meyer Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs Clin. Pharmacol. Ther. 43 6 1988 630 635
20. T. Aoyama, S. Yamano, D.J. Waxman, D.P. Lapenson, U.A. Meyer, and V. Fischer Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine J. Biol. Chem. 264 18 1989 10388 10395
21. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano Human P-glycoprotein transports cyclosporin A and FK506 J. Biol. Chem. 268 9 1993 6077 6080
22. L.S. Gan, M.A. Moseley, B. Khosla, P.F. Augustijns, T.P. Bradshaw, and R.W. Hendren CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells Drug Metab. Dispos. 24 3 1996 344 349
23. V.J. Wacher, J.A. Silverman, Y. Zhang, and L.Z. Benet Role of P-glycoprotein and cytochrome P4503A in limiting oral absorption of peptides and peptidomimetics J. Pharm. Sci. 87 11 1998 1322 1330
24. K.S. Lown, R.R. Mayo, A.B. Leichtman, H.L. Hsiao, D.K. Turgeon, and P. Schmiedlin-Ren Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine Clin. Pharmacol. Ther. 62 3 1997 248 260
25. M.F. Hebert Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery Adv. Drug Deliv. Rev. 27 2/3 1997 201 214
26. G.Y. Kwei, R.F. Alvaro, Q. Chen, H.J. Jenkins, C.E. Hop, and C.A. Keohane Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein Drug Metab. Dispos. 27 5 1999 581 587
27. L.D. Bowers Studies of cyclosporine and metabolite toxicity in renal and hepatocyte culture systems Transplant Proc. 22 3 1990 1135 1136
28. K.R. Copeland, J.A. Thliveris, and R.W. Yatscoff Toxicity of cyclosporine metabolites Ther. Drug Monitor. 12 6 1990 525 532
29. A. Lemoine, D. Azoulay, J.M. Gries, A. Dennison, D. Castaing, and G. Fredj Relationship between graft cytochrome P-4503A content and early morbidity after liver transplantation Transplantation 56 6 1993 1410 1414
30. L.E. Schmidt, A. Rasmussen, P. Kirkegaard, and K. Dalhoff Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients Transplantation 76 2 2003 358 363
31. U. Christians, K. Kohlhaw, J. Budniak, J.S. Bleck, R. Schottmann, and H.J. Schlitt Cyclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of cyclosporin metabolites with nephrotoxicity Eur. J. Clin. Pharmacol. 41 4 1991 285 290
32. M. Kempkes-Koch, M. Fobker, M. Erren, C. August, U. Gerhardt, and B. Suwelack Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy Transplant Proc. 33 3 2001 2167 2169
33. E.G. Schuetz, J.D. Schuetz, W.M. Grogan, A. Naray-Fejes-Toth, G. Fejes-Toth, and J. Raucy Expression of cytochrome P4503A in amphibian, rat, and human kidney Arch. Biochem. Biophys. 294 1 1992 206 214
34. B.D. Haehner, J.C. Gorski, M. Vandenbranden, S.A. Wrighton, S.K. Janardan, and P.B. Watkins Bimodal distribution of renal cytochrome P4503A activity in humans Mol. Pharmacol. 50 1 1996 52 59
35. R.C. Givens, Y.S. Lin, A.L. Dowling, K.E. Thummel, J.K. Lamba, and E.G. Schuetz CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults J. Appl. Physiol. 95 3 2003 1297 1300
36. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, and J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat. Genet. 27 4 2001 383 391
37. E. Hustert, M. Haberl, O. Burk, R. Wolbold, Y.Q. He, and K. Klein The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 9 2001 773 779
38. Y.S. Lin, A.L. Dowling, S.D. Quigley, F.M. Farin, J. Zhang, and J. Lamba Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism Mol. Pharmacol. 62 1 2002 162 172
39. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, and C.L. Marsh Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 283 3 1997 1552 1562
40. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
41. T. Omura, and R. Sato The carbon monoxide-binding pigment of liver microsomes J. Biol. Chem. 239 1964 2370 2385
42. K.E. Thummel, D.D. Shen, T.D. Podoll, K.L. Kunze, W.F. Trager, and P.S. Hartwell Use of midazolam as a human cytochrome P4503A probe. I. In vitro-in vivo correlations in liver transplant patients J. Pharmacol. Exp. Ther. 271 1 1994 549 556
43. E.M. Gillam, Z. Guo, Y.F. Ueng, H. Yamazaki, I. Cock, and P.E. Reilly Expression of cytochrome P4503A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities Arch. Biochem. Biophys. 317 2 1995 374 384
44. M.B. Fisher, S.J. Thompson, V. Ribeiro, M.C. Lechner, and A.E. Rettie P450-catalyzed in-chain desaturation of valproic acid: isoform selectivity and mechanism of formation of Delta 3-valproic acid generated by baculovirus-expressed CYP3A1 Arch. Biochem. Biophys. 356 1 1998 63 70
45. i values and impact of CYP3A5 expression Drug Metab. Dispos. 27 2 1999 180 187
46. J. Simpson, Q. Zhang, P. Ozaeta, and H. Aboleneen A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry Ther. Drug Monitor. 20 3 1998 294 300
47. V. Havlicek, A. Jegorov, P. Sedmera, and M. Ryska Sequencing of cyclosporins by fast atom bombardment and linked-scan mass spectrometry Org. Mass Spectrom. 28 12 1993 1440 1447
48. K.K. Khan, Y.Q. He, M.A. Correia, and J.R. Halpert Differential oxidation of mifepristone by cytochromes P4503A4 and 3A5: selective inactivation of P4503A4 Drug Metab. Dispos. 30 9 2002 985 990
49. J.C. Gorski, S.D. Hall, D.R. Jones, M. VandenBranden, and S.A. Wrighton Regioselective biotransformation of midazolam by members of the human cytochrome P4503A (CYP3A) subfamily Biochem. Pharmacol. 47 9 1994 1643 1653
50. A. Bader, T. Hansen, G. Kirchner, C. Allmeling, A. Haverich, and J.T. Borlak Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions Br. J. Pharmacol. 129 2 2000 331 342
51. Y. Lin, P. Lu, C. Tang, Q. Mei, G. Sandig, and A.D. Rodrigues Substrate inhibition kinetics for cytochrome P450-catalyzed reactions Drug Metab. Dispos. 29 4 Pt 1 2001 368 374
52. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004;32(10).
53. V. Haufroid, M. Mourad, V. Van Kerckhove, J. Wawrzyniak, M. De Meyer, and D. Eddour The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 3 2004 147 154
54. D.A. Hesselink, R.H. van Schaik, I.P. van der Heiden, M. van der Werf, P.J. Gregoor, and J. Lindemans Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin. Pharmacol. Ther. 74 3 2003 245 254
55. A.E. Vickers, V. Fischer, S. Connors, R.L. Fisher, J.P. Baldeck, and G. Maurer Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines Drug Metab. Dispos. 20 6 1992 802 809
56. M.A. Gibbs, K.L. Kunze, W.N. Howald, and K.E. Thummel Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole Drug Metab. Dispos. 27 5 1999 596 599